# Prediction of antidepressant side effects in the Genetic Link to Anxiety and Depression Study

3

Danyang Li, PhD 1\*, Yuhao Lin, MSc 1, Helena L. Davies, PhD 1,2,3, Johan Källberg
Zvrskovec, MSc 1, Rujia Wang, PhD 1, Chérie Armour, PhD 4, Ian R. Jones, PhD 5,
Andrew M. McIntosh, MD 6, Nathalie Kingston, PhD 7, John R. Bradley, PhD 7,
Christopher Hübel, PhD 1,8, Gursharan Kalsi, PhD 1,9, Jonathan R. I. Coleman, PhD
1,9, the NIHR BioResource consortium, Matthew Hotopf, PhD 9,10, Thalia C. Eley,
PhD 1, Evangelos Vassos, PhD 1, Raquel Iniesta, PhD 11,12, Gerome Breen, PhD 1\*

10

1 1 = Social, Genetic and Developmental Psychiatry Centre, King's College London,
 London

- 13 2 = Mental Health Center Ballerup, Copenhagen University Hospital Mental Health
- 14 Services CPH, Center for Eating and feeding Disorders Research, Denmark
- 15 3 = Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde,
- 16 Institute of Biological Psychiatry, Denmark
- 17 4 = Research Centre for Stress Trauma and Related Conditions (STARC), School of
- 18 Psychology, Queen's University Belfast, Belfast
- 19 5 = National Centre for Mental Health, Cardiff University, Cardiff
- 20 6 = Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh,
- 21 Edinburgh
- 22 7 = University of Cambridge, Cambridge
- 23 8 = National Centre for Register-based Research, Aarhus University, Aarhus
- 24 9 = UK National Institute for Health and Social Care Research (NIHR) Biomedical
- 25 Research Centre for Mental Health, South London and Maudsley Hospital, London
- 26 10 = Institute of Psychiatry, Psychology and Neuroscience, King's College London,
- 27 London
- 11 = Department of Biostatistics & Health Informatics, King's College London, London
- 29 12 = King's Institute for Artificial Intelligence, King's College London, London
- 30 \* = Corresponding authors

#### 31 Abstract:

Antidepressants are the most common treatment for moderate or severe depression. 32 Side effects are crucial indicators for antidepressants, but their occurrence varies 33 widely among individuals. In this study, we leveraged genetic and medical data from 34 self-reported questionnaires in the Genetic Links to Anxiety and Depression (GLAD) 35 study to build prediction models of side effects and subsequent discontinuation across 36 37 three antidepressant classes (SSRI, SNRI, tricyclic antidepressant (TCA)) at the first and the last (most recent) year of prescription. We included 259 predictors spanning 38 genetic, clinical, illness, demographic, and antidepressant information. Six prediction 39 models were trained, and their performance was compared. The final dataset 40 comprised 4,354 individuals taking SSRI in the first prescription and 3,414 taking SSRI, 41 SNRI or TCA in the last year of prescription. In the first year, the best area under the 42 receiver operating characteristic curve (AUROC) for predicting SSRI discontinuation 43 44 and side effects were 0.65 and 0.60. In the last year of SSRI prescription, the highest AUROC reached 0.73 for discontinuation and 0.87 for side effects. Models for 45 predicting discontinuation and side effects of SNRI and TCA showed comparable 46 performance. The history of side effects and discontinuation of antidepressant use 47 were the most influential predictors of the outcomes in the last year of prescription. 48 When examining 30 common antidepressant side effect symptoms, most of them were 49 differentially prevalent between antidepressant classes. Our findings suggested the 50 feasibility of predicting antidepressant side effects using a self-reported questionnaire. 51 particularly for the last prescription. These results could contribute valuable insights 52 for the development of clinical decisions aimed at optimising treatment selection with 53 54 enhanced tolerability but require replication in medical record linkage or prospective 55 data.

#### 56 Introduction

Antidepressants are commonly prescribed medications, but both clinicians and their patients 57 face uncertainty and concerns due to a lack of ability to accurately predict who will 58 experience side effects. The majority of individuals taking antidepressants report 59 experiencing at least one side effect<sup>1</sup>. In clinical trials, more than half of individuals 60 discontinue medication within six months of starting treatment, with side effects being the 61 most commonly cited contributing factor<sup>2</sup>. Side effects often result in staged and/or 62 inadequate dosing, which is associated with a lack of remission or delayed remission<sup>1</sup>. Some 63 64 side effects, such as fatigue, sleep change, and cognitive impairment phenomenologically overlap with depression symptoms and related comorbidities, such as anxiety. This overlap 65 further complicates treatment decisions such as dose adjustment or the selection of 66 appropriate initial or alternative medications. 67

68

Tricyclic antidepressants (TCAs) were the dominant medications used to treat depression 69 before the 1990s. Currently, second-generation antidepressants such as selective serotonin 70 71 reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line treatments for depression. All antidepressants operate by targeting monoamine 72 neurotransmitters to increase activation of postsynaptic receptors<sup>3</sup>. Individuals taking TCAs 73 are more likely to discontinue treatment, to experience lower tolerability and increased 74 75 cardiac side effects compared to those taking second-generation antidepressants<sup>4,5</sup>. Conversely, side effects such as sexual dysfunction, insomnia, nausea, irritability, and 76 anxiety are more prominent response to SSRIs and SNRIs<sup>6</sup>. Nevertheless, clarity over which 77 78 side effect symptoms are specific to different antidepressants is lacking.

79

Within the same type of drugs, there is considerable inter-individual variance in side effect 80 81 occurrence and severity. Various factors, including sex<sup>7</sup> and clinical features like depression 82 severity<sup>8</sup>, have been associated with antidepressant tolerability and adherence. Pharmacogenomic testing is an emerging strategy to inform medication selection and dose 83 84 decisions based on individual genetic variations. Variants such as those found in the 85 cytochrome P450 genes CYP2C19 and CYP2D6 are linked to antidepressant metabolism and clearance. They can cause differences in enzyme activity that influence antidepressant 86 response and side effects, although their reported effects are inconsistent among studies<sup>9,10</sup>. 87 In addition, polygenic scores (PGSs) related to depression have been reported to be 88 89 predictive of side effects that overlap with depressive symptoms, such as suicidality and anxiety<sup>11</sup>. The multi-PGS framework allows combined analysis of multiple relevant PGSs 90 associated with a specific trait or outcome, with the aim of improved prediction accuracy 91 compared to a single PGS<sup>12,13</sup>. 92

93

94 Side effects could be influenced by a combination of many factors spanning attributions, 95 illness representations, personality, clinical, genetic, and social factors. In contrast with 96 traditional statistical models, machine learning methods can optimally be used for prediction 97 analyses involving large datasets that show complex interrelationships and are very often 98 high-dimensional. Machine learning can effectively capture both linear and non-linear 99 relationships across multiple data sources<sup>14,15</sup>. These methods employ data-resampling 100 procedures in holdout samples to estimate models' parameters and to internally validate

inter-variable relationships in unseen individuals. To achieve generalisation, models are 101 validated in independent samples not used for model building. Published machine learning 102 models have used demographics, diagnoses, laboratory values and medication information 103 104 across various drugs to predict side effects in clinical trials and electronic health record data<sup>16</sup>. For antidepressants, treatment response and improvement in depression severity 105 have been mostly studied within groups of individuals receiving the same treatment<sup>17</sup>. 106 However, few studies have investigated side effect prediction combining genetic and clinical 107 measures<sup>18</sup>. 108

109

In this study, we leveraged self-reported questionnaires and genome-wide genetic data from 110 the Genetic Links to Anxiety and Depression Study (GLAD)<sup>19</sup> to build prediction models of 111 side effect occurrence for three common antidepressant classes: SSRIs, SNRIs, and TCAs. 112 Self-reported side effects and discontinuation (due to side effects) were obtained from the 113 first and last (most recent) year of prescription. We applied six machine learning models 114 incorporating 259 predictors covering five categories: genetic variables, clinical measures, 115 demographic characteristics, illness information, and antidepressant history (Figure 1). We 116 also presented the prevalence, correlation, and association with antidepressant classes in 117 30 common side effect symptoms. By integrating data on multiple antidepressants in a large 118 cohort, we aimed to provide a more realistic portrayal of real-world drug prescriptions and 119 enhance the potential for early and accurate detection of side effects in personalised 120 121 antidepressant prescriptions.



125 Methods

122 123

124

126 Study population

All participants in this study were from the Genetic Links to Anxiety and Depression (GLAD) 127 Study. In summary, individuals from the general population in the UK were recruited using 128 a combination of traditional and social media, as well as clinic-based recruitment, based on 129 the eligibility criterion of meeting a DSM-5 diagnosis for major depressive disorder (MDD) 130 or any anxiety disorder. Participants were invited to complete online sign-up questionnaires, 131 covering demographics, illness, and psychological and behavioural phenotypes relevant to 132 anxiety and depression. Subsequently, participants filled out additional questionnaires that 133 more deeply detailed medication use, psychiatric disorders beyond depression and anxiety, 134 lifestyle, and personal history. A more comprehensive description can be found in Davies et 135 136 al<sup>19</sup>. GLAD received ethical approval from the London - Fulham Research Ethics Committee (REC reference: 18/LO/1218), while the NIHR BioResource obtained approval from the East 137 of England - Cambridge Central Committee (REC reference: 17/EE/0025). 138

139

## 140 Polygenic score (PGS)

Detailed genotyping and imputation steps can be found in Supplementary Methods. Imputed 141 genotypes were aligned with the Hapmap3 reference panel to remove strand-ambiguous 142 SNPs and for PGS calculation. PGSs were computed using MegaPRS<sup>20</sup> via the GenoPred 143 pipeline<sup>21</sup>. PGSs were reference standardised: MegaPRS was used to first construct PGS 144 in the 1000 Genome European reference panel, following which the mean and standard 145 deviation of PGS output in GLAD samples were scaled to the mean and standard deviation 146 of the reference. GWAS summary statistics from 102 traits were incorporated for both 147 reference PGSs and GLAD PGSs in this study (Supplementary Table 1). PGSs from the 148 GLAD were further rescaled using the reference PGSs to ensure a comparable distribution 149 150 with the reference.

151

#### 152 Inferred cytochrome metabolic phenotypes

153 We selected CYP2C19 and CYP2D6 to examine their pharmacogenetic effects, as suggested by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline 154 for SSRIs and Tricyclic antidepressants<sup>22,23</sup>. Phasing was conducted using SHAPEIT4 155 software for the regions of CYP2C19 and CYP2D6 obtained from PharmGKB 156 (https://www.pharmgkb.org/)<sup>24</sup>. Star alleles were identified by SNPs matched between the 157 phased data and CPIC definitions (https://cpicpgx.org/; downloaded June 2022)<sup>25</sup>. Allele 158 function and activity values were annotated to include alleles with no. decreased, normal. 159 and increased function (https://cpicpgx.org/)<sup>22</sup>. Metabolic phenotypes of CYP2C19, 160 including poor, intermediate, normal, rapid/ultrarapid, were inferred from genotypes, and 161 classified based on CPIC guidelines. CYP2D6 phenotypes (poor, intermediate, normal) 162 were defined by the consensus recommendations of CPIC and the Dutch Pharmacogenetics 163 Working Group (DPWG)<sup>26</sup>. Since structural variants of CYP2D6 were unavailable in the 164 imputed genotype data, no rapid/ultrarapid metabolisers were identified. The activity score 165 was determined by summing the activity values of the two star alleles in each individual. 166

167

#### 168 Outcomes

169 Participants provided self-reported side effect data for commonly prescribed 170 antidepressants in the UK, including eight selective serotonin reuptake inhibitors (SSRIs), 2 171 serotonin and norepinephrine reuptake inhibitors (SNRIs), and 10 tricyclic antidepressants

172 (TCAs) (Supplementary Table 2). Participants were asked about any experienced side effects from the prescribed antidepressants and then selected one or more side effects from 173 a list of 30 common symptoms, including dry mouth, sweating, nausea, vomiting, diarrhoea, 174 constipation, headache, dizziness, memory problems, attention/concentration difficulties. 175 shaking. muscle pain. sleepiness/drowsiness, difficulty getting to sleep, increased anxiety, 176 fast heartbeat, restlessness/agitation, fatigue or weakness, changes in appetite, weight gain, 177 weight loss, itching, rash, runny nose, reduced sexual desire/function, menstrual 178 problems/irregularities, blurred vision, suicidal thoughts, attempted suicide, and others. 179 180 Discontinuation was indicated by the response to whether the participant had to stop taking the antidepressant due to side effects. 181

182

183 Antidepressants were ordered by the age at which they were prescribed for each participant. In this study, we included antidepressants prescribed in the first and the most recent (last) 184 year. Information on side effects and discontinuation due to side effects were collected for 185 each antidepressant of each individual. To minimise self-report errors, we limited 186 187 participants to those who reported at most three different antidepressants during both the first and the last year. Specifically, for first year antidepressants, we focused on whether 188 each participant experienced any side effects or discontinuation with SSRI drugs. For last 189 year antidepressants, we considered the occurrence of side effects and discontinuation for 190 SSRI, SNRI, and TCA antidepressants. In cases where participants were prescribed more 191 192 than one antidepressant within the same class in either year, side effects and 193 discontinuation were counted if they occurred with either one of the drugs.

194

#### 195 **Predictors**

196 We curated 259 items across five categories, including demographics, illness, clinical evaluation, antidepressant history, and genetics, to serve as predictor variables. Core 197 198 demographic details (e.g., sex, employment status, years of education, marital status, BMI) and health conditions (neurological, allergic, cardiovascular, respiratory, digestive, 199 200 inflammatory, cancer-related) were obtained from the sign-up questionnaire. Clinical and psychiatric symptoms were assessed through various measures, including lifetime 201 measures of MDD and anxiety (adapted from the Composite International Diagnostic 202 Interview - Short Form (CIDI-SF)), Standardised Assessment of the Severity of Personality 203 Disorders (SASPD), and lifetime assessment of panic disorder (adapted from DSM-5/ICD-204 11 checklists). In terms of antidepressant histories, we considered antidepressant initiation 205 206 and last prescription age, the total number and duration of antidepressants taken, and the average number of side effect occurrence, discontinuation, and efficacy (effectiveness of 207 each antidepressant) calculated from all antidepressants taken before the last year. Genetic 208 factors included PGSs for 102 traits and cytochrome metabolic phenotypes, as described 209 above. The complete list of predictors was provided in Supplementary Table 3. 210

To ensure all predictors in the model have been characterised before the outcome, we chose predictors that preceded the antidepressant initiation including all genetic variables, sex, ethnicity, antidepressant initiation age, lifetime depression and anxiety symptoms to predict outcomes of antidepressants taken in the first year. All predictors were added to the model for the prediction of antidepressants taken in the last year.

216

#### 217 **Prediction modelling**

# 218 – Data processing

We removed predictors with missing values > 30%. The remaining were imputed using the random forest algorithm in the MICE package<sup>27</sup>. Predictors with either zero variance or a correlation higher than 0.8 with another predictor were excluded. For categorical factors with more than two categories, they were converted into a set of binary dummy variables in the elastic net and SVM models. Normalisation was applied to each predictor to achieve a standard deviation of one and a mean of zero before training the SVM.

# 225

#### 226 -- Model building

227 We applied six prediction models, including elastic net, support vector machine (SVM) with radial basis function (RBF) and polynomial kernels, XGBoost, random forest, and cubist in 228 this study. A stratified split was employed based on the outcome, randomly allocating 80% 229 for the training data and the remaining 20% for the testing data, maintaining the same 230 outcome proportions as in the original population in each split. Within the training data, a 5-231 232 fold stratified cross-validation with 5 repeats were conducted, assigning 20% of the data as a validation set for hyperparameter prioritisation and the remainder for model training. The 233 234 receiver operating characteristic area under the curve (AUROC) was assessed in the 235 validation set to identify models that maximise performance. The best performing models, along with their hyperparameter combinations, were extracted and employed to predict the 236 outcome class in the test data. Beyond AUROC, we reported accuracy and precision-recall 237 area under the curve (AUPRC) of test data for each model. After model training, a logistic 238 239 regression was fitted between the probability estimates and the true probabilities to produce 240 the calibrated estimates. More description of each model and data processing can be found 241 in Supplementary Methods.

242

#### 243 -- Feature importance

For every predictor category (genetics, demographics, illness, clinical and antidepressant information) in the outcomes of drug prescriptions during the last year, we evaluated their importance by excluding the corresponding category of predictors and retrained the model using the same strategy for model building and estimation as described above. The relative reduction in AUROC was calculated for each predictor category compared to the models with the complete set of predictors.

250

# 251 -- Prediction across antidepressant classes

For each antidepressant class in the last year of prescription, we compared the model performance between the same drug (training and testing data within the same drug class) and cross drug (training and testing data across different drug classes) analyses to determine the specificity of the model to the drug class. The models with the best performance, identified through the same drug analysis, were then tested on data from other drugs. The Kruskal-Wallis test was used to examine the differences in AUROC values obtained from the same antidepressant class and cross-class analyses.

259

#### 260 Association of side effects with predictors at the last prescription

To further make each predictor's effect more interpretable and understandable, a univariate logistic regression was performed between each predictor and the six outcomes at the last prescription to evaluate their associations. The false discovery rate was used to adjust the statistical significance for each outcome.

265

#### 266 Correlation of side effect symptoms and drug effect difference

Tetrachoric correlations were applied to assess the correlation of side effect symptoms 267 among SSRIs, SNRIs, and TCAs. Each side effect symptom was coded as a binary variable, 268 with 1 indicating the occurrence of the symptom with any prescribed drugs and 0 showing 269 270 the absence of the symptom. Hierarchical clustering analysis measured by Euclidean 271 distance was conducted on the distance matrix derived from the correlation matrix of the symptoms. A generalised linear mixed model was constructed to investigate the impact of 272 drug class on each side effect symptom, with drug class as a fixed variable and individual 273 ID as a random variable. SSRIs were set as the reference for comparison with SNRIs and 274 275 TCAs. Statistical significance was adjusted using the Bonferroni test across the 30 276 symptoms.

277

#### All prediction modelling and association analyses were performed using R v4.2.3<sup>28</sup>.

#### 279

#### 280 **Results**

## 281 Participant characteristics

All participants in this study were part of the Genetic Links to Anxiety and Depression (GLAD) Study. Overall, 8219 individuals completed the antidepressant questionnaire, and 5358 had available genetic data. In the first year of prescription, most individuals were prescribed SSRIs, with 45% continuing SSRIs and 19.0% transitioning to other antidepressants in the second prescription year (Supplementary Figure 1).

287

The average prevalence of side effects and discontinuation during the initial five prescription 288 years was 74% and 29%, respectively (Figure 2). In the first year, 6% of participants who 289 290 initially experienced side effects reported none in the second year. Conversely, 20% of participants without side effects in the first year experienced at least one side effect symptom 291 in the second year (Supplementary Table 4). For the discontinuation outcome, 33% of 292 participants transitioned from discontinuation to no discontinuation in the first two years of 293 294 prescription. Approximately 8% of participants experienced discontinuation in the second prescription year after having no discontinuation in the first year (Supplementary Table 4). 295

296

For the prediction models, we included 4354 individuals for SSRIs in the first year of prescription. In addition, 3414 had data for an antidepressant prescription in the last year, comprising 60% (2036) on SSRIs, 22% (753) on SNRIs, and 29% (982) on TCAs. In the initial year, 73% of participants taking SSRIs experienced side effects, and 32% reported discontinuation. In the last year, the reported side effects prevalence for SSRIs was 75%, lower than SNRIs (84%) and TCAs (76%). Discontinuation was highest for TCAs (37%), followed by SSRIs (20.7%) and SNRIs (20.6%) (Table 1).



304

Figure 2. Side effects and discontinuation occurrence at the first five years of prescription, where the x-axis represented each individual (ordered by yes first), and the y-axis showed the time of prescription.

308 309

Table 1. Side effects and discontinuation at the prescription of the first and last year

	Discontinuation	Side effect symptoms
Prescription at the first year (N (yes%))		
SSRI	3947 (31.6)	4286 (73.3)
Prescription at the last year (N (yes%))		
SSRI	1770 (20.7)	1986 (75.3)
SNRI	640 (20.6)	733 (83.5)
TCA	834 (37.2)	959 (76.4)

310

#### 311 Prediction of antidepressant side effects and discontinuation

In the initial year of SSRIs prescription, the best AUROCs for predicting discontinuation and 312 side effects were 0.65 and 0.60, respectively, achieved by XGBoost (Figure 3a). In the last 313 year of SSRIs prescription, the highest AUROC observed for discontinuation was 0.73, and 314 0.87 for side effects (Figure 3a). Models including elastic net, random forest and XGBoost 315 achieved AUROC values around 0.70 for discontinuation and above 0.85 for side effects. 316 For SNRIs, the best AUROC was observed in random forest, with 0.71 for discontinuation 317 and 0.80 for side effects. The best models for TCAs had AUROC of 0.71 and 0.87 for 318 predicting discontinuation and side effects, respectively (Supplementary Figure 2). More 319 detailed results for AUROC, AUPRC and accuracy were provided in Supplementary Table 320 321 5.



Figure 3. ROC curve (a) and feature importance (b) of SSRIs discontinuation and side effects. Antidepressant history included information of antidepressant initiation and last prescription age, total number and duration of prescribed antidepressants, and the average number of efficacy ratings, side effect occurrence, and discontinuation of all antidepressants taken before the last year of prescription.

333

For the last year of prescription, we performed cross-class analysis to assess model specificity, comparing the performance of the same training data when tested on different antidepressant classes. For both discontinuation and side effects, the Kruskal-Wallis test revealed no statistically significant differences between the same antidepressant class and different classes for any drug-derived models. This suggested that these models were nonspecific to antidepressant class in the last year of prescription (Supplementary Figure 3).

340

#### 341 Feature importance at the prescription of last year

Next, for each drug class in the last prescription, we evaluated the importance of each 342 343 predictor category by removing corresponding categories one at a time and retrained the model selected by the best performance of AUROC. We chose XGBoost in this step given 344 345 it showed superior performance on average across all outcomes described above. Overall, 346 antidepressant history emerged as the most influential category in predicting discontinuation and side effects during the last year of prescription, with a relative reduction in AUROC 347 ranging from 11.4% to 24.0% for discontinuation and 20.4% to 37.1% for side effects (Figure 348 3b, Supplementary Figure 4). Other clinical measures made a modest contribution to the 349 350 model for discontinuation, with an impact of 10.0% in SSRIs, 1.4% in SNRIs, and 3.0% in TCAs. Their impact on side effects was considerably less, with the highest relative AUROC 351 reduction of 1.0% in TCA drugs. Genetic factors exhibited the highest impact (1.1%) in 352 predicting side effects and 0.3% for discontinuation (Supplementary Figure 4). 353

354

#### 355 Association at the prescription of last year

356 We also conducted univariate logistic regression to examine the association of side effects and discontinuation outcomes with individual features during the last year of prescription. 357 As expected, we observed a strong association between side effect/ discontinuation history 358 and both outcomes across all antidepressant classes (Supplementary Figure 6). For the 359 discontinuation outcome, clinical measures related to depression (low mood, number of 360 episodes, thoughts about death, group/talking therapy), anxiety (anxiety symptoms, duration 361 of worry), and panic disorder (choking, strong fears of attack situations, panic symptoms, 362 medical conditions) were linked to SSRIs, while no significance was observed in other drugs. 363 364 For side effects, antidepressant prescription age and panic disorders (including panic symptoms, feeling hot or cold) showed associations across all drugs. Other features, 365 including marital status, educational attainment, depressive symptoms, and panic symptoms 366 (strong fears of attack situations, fear of losing control or going crazy, sweating) were 367 associated with any two of the three antidepressant classes (Supplementary Figure 6). 368 369

#### 370 Side effect symptoms correlation and drug specificity

To investigate the correlations among side effect symptoms and identify how they differed 371 372 across drug classes, we collected 30 common symptoms from the self-reported questionnaire. In Figure 4, we present the prevalence of side effect symptoms for each drug 373 class across all prescriptions. The most reported side effects included reduced sexual desire, 374 dry mouth, sleepiness/drowsiness, and weight gain, while rash, runny nose, menstrual 375 376 irregularities, and weight loss had the lowest prevalence. TCAs had most individuals 377 reporting sleepiness/drowsiness, weight gain, dry mouth, and changes in appetite. Reduced sexual desire, nausea, dry mouth, and concentration difficulties were the most common 378 379 symptoms of SSRIs. Reduced sexual desire, sweating, dry mouth, and nausea were 380 predominantly reported in SNRIs (Supplementary Table 6).

381





Figure 4. Prevalence of side effect symptoms in antidepressant classes. Symptoms were ordered by their prevalence in the studied population.

385

For individuals who reported more than one side effect symptom, we examined the 386 correlations between these symptoms across medications. Significant correlations were 387 evident between certain symptoms, such as nausea and vomiting (r = 0.797), memory 388 problems and concentration difficulties (r = 0.803), itching and rash (r = 0.782), as well as 389 390 suicidal thoughts and attempted suicide (r = 0.861). Moderate correlations were observed between sleepiness/drowsiness and fatigue or weakness (r = 0.663), headache and 391 392 dizziness (r = 0.653), and a symptom cluster comprising increased anxiety, restlessness/agitation, and fast heart beat (increased anxiety vs restlessness/agitation: r = 393 394 0.743; fast heart beat vs restlessness/agitation: r = 0.689; fast heart beat vs increased anxiety: r = 0.639, Supplementary Figure 6). 395

396

Finally, we used generalised linear mixed models to investigate the impact of antidepressant classes on each side effect symptom. Compared to SSRIs, SNRIs and TCAs were associated with fewer reports of symptoms like suicidal thoughts, attempted suicide, increased anxiety, diarrhoea, weight loss, vomiting, restlessness/agitation, reduced sexual desire, rash, headache, and difficulty getting to sleep. Conversely, constipation showed a

higher occurrence in both SNRIs and TCAs compared to SSRIs. Symptoms such as weight
gain, sleepiness/drowsiness, fatigue or weakness, and changes in appetite were more likely
to occur in TCAs than SSRIs but were comparable between SNRIs and SSRIs. Dry mouth
and concentration difficulties showed no significant differences across all drugs (Figure 5,
Supplementary Table 7).

407



408

Figure 5. Association of side effect symptoms with drug classes using SSRIs as reference. Each bar
 represents the effect of SNRIs/TCAs on side effect symptoms compared to SSRIs with 95%
 confidence intervals.

412

# 413 Discussion

In this study, we find evidence that self-reported side effects and discontinuation (due to 414 side effects) can be predicted using questionnaires and genetic information, particularly for 415 the most recent antidepressant treatments. Among all predictors, antidepressant history 416 including side effects and discontinuation history showed the primary contribution, indicating 417 individuals tend to have consistent side effect occurrence across different prescriptions. 418 When examining 30 common antidepressant side effect symptoms, the most prevalent 419 symptoms were lower sexual desire, dry mouth, and sleepiness/drowsiness. Most of the 30 420 symptoms were differentially prevalent between antidepressant classes. 421 422

423 Using machine learning, our results confirmed predicting side effect occurrence was more accurate for the last antidepressant prescription compared to the initial treatment, 424 particularly when considering antidepressant history. Relatively few studies have 425 investigated how drug history influences adverse reactions to the current treatment. 426 427 However, similar findings are reported in the available literature. For example, the risk of gastrointestinal side effects in nonsteroidal anti-inflammatory drugs (NSAIDs) could be 428 increased if previous NSAID intolerance was identified<sup>29</sup>. In hospitalised older patients, a 429 history of experiencing harmful outcomes from medications in the preceding year was shown 430 to predict adverse drug effects from current medications<sup>30</sup>. A study on treatment-resistant 431 depression also found that a history of electroconvulsive therapy and unsuccessful 432 antidepressant trials were associated with the outcome of vagus nerve stimulation<sup>31</sup>. Despite 433 this, medication history of side effects and discontinuation has been largely overlooked in 434 prediction studies. 435

436

437 Antidepressant side effects have been linked to the severity of depression, polypharmacy, and comorbid status<sup>8,32,33</sup>. Similarly, we observed that clinical measures such as a higher 438 score of depression/panic symptoms and number of episodes could increase the risk of side 439 440 effects and discontinuation, but their effects were less pronounced than the impact of side effects or discontinuation history. We also identified a large correlation of side effect history 441 among antidepressant classes above 0.62 (SSRIs vs SNRIs: r = 0.66, SSRIs vs TCAs: r = 442 0.68, SNRIs vs TCAs: r = 0.62), suggesting the occurrence of self-reported side effects might 443 444 be underlined by other factors regardless of antidepressant class, such as pharmacological, or genetic factors, as indicated in other studies<sup>11</sup>. The role of other factors such as 445 expectation bias should also be considered, especially when using self-reported data<sup>33</sup>. 446

447

Genetic predictors, including pharmacokinetic features (CYP2C19 and CYP2D6 metabolic 448 phenotypes) along with polygenic risk for multiple disorders and traits only marginally 449 improved model performance in the last prescription. This finding aligned with Poweleit et 450 al.<sup>18</sup>, where the predictive ability of CYP2C19 phenotypes was limited compared to 451 pharmacokinetic parameters including clearance, half-life for escitalopram and sertraline 452 side effects. CYP2C19 poor metabolisers exhibited an OR of 1.99 for the occurrence of the 453 last SSRI side effect in our univariate association analysis, showing a comparable effect 454 size to other studies<sup>10,34</sup>. However, statistical significance was not achieved due to limited 455 power. We did not find an association between CYP2D6 metabolic status and any side effect 456 outcomes and it is important to note that the genotype-determined metabolic phenotype in 457 our study has a lower ability to identify star alleles, particularly for CYP2D6. Approximately 458 7% of CYP2D6 variants are structural variants, so the star allele calls and metabolic 459 phenotype imputation would be influenced by these missing variants in the genotype leading 460 to the misclassification of metabolic phenotypes and higher false negative findings<sup>25,35</sup>. 461

462

We observed a modest predictive ability of PGSs for side effects and discontinuation. Previous studies have reported PGSs for depression, schizophrenia, attention-deficit hyperactivity disorder, and bipolar disorder with treatment response or resistance, but these results mostly yielded no strong evidence of significant associations<sup>36,37</sup>. A study showed PGSs were associated with corresponding side effect symptoms, such as the PGS for

depression was linked to depressive symptoms including suicidality and anxiety, and the 468 BMI PGS was associated with weight gain side effects<sup>11</sup>. However, the explained variance 469 attributed to these PGSs (approximately 1%) to predict side effect outcomes was low. 470 Although our study integrated multiple PGS traits to enhance prediction power<sup>12</sup>, we lacked 471 472 PGSs directly related to antidepressant side effects or responses, which need to be the subject of larger studies<sup>37</sup>. We also acknowledge the need for a larger sample size to fully 473 reflect their predictive ability<sup>38</sup>. Genetic contribution to antidepressant side effects would be 474 further improved with more precise measures of pharmacogenomic phenotypes and 475 476 sufficient sample size to maximise the PGS evaluation.

478 As mentioned above, the most commonly reported side effects included reduced sexual 479 desire, dry mouth, sleepiness/drowsiness, and weight gain – consistent with findings from 480 other studies<sup>1,32</sup>. Some symptoms, such as dry mouth, were common in all antidepressant classes, while others, such as reduced sexual desire, were mostly associated with SSRIs 481 482 or SNRIs, and drowsiness was most prevalent in TCAs. Previous studies have indicated SSRIs were associated with gastrointestinal symptoms, anxiety, insomnia, and sexual side 483 484 effects, and TCAs broadly conferred an increased risk of weight gain, sedation, sexual dysfunction, and anticholinergic symptoms<sup>4,6,32,39,40</sup>. We confirmed SSRIs were more likely 485 to cause gastrointestinal symptoms (vomiting, diarrhoea, nausea), restlessness agitation, 486 anxiety, weight loss, reduced sexual desire, and difficulty getting to sleep, while individuals 487 488 taking TCAs experienced more weight gain, sleepiness/drowsiness, change in appetite, and fatigue or weakness. Anticholinergic symptoms such as constipation were more common 489 490 with TCAs than SSRIs while dry mouth and concentration difficulties showed no differences 491 among drug classes.

492

477

493 We found suicidality (attempted suicide and suicidal thoughts) was mostly reported in SSRIs compared to SNRIs or TCAs. The FDA has added a black box warning for increased 494 suicidality risk among adolescents aged 18-24 with SSRIs prescription<sup>4,41</sup>. However, the 495 effectiveness of this warning is disputed, given increased suicidality among those with 496 497 severe depression who were not prescribed antidepressants as a result of the warning<sup>42</sup>. While SSRIs were found to increase the risk of suicidality when prescribed for adolescents, 498 the risk was reduced in adults<sup>40</sup>. Among people aged 20 or older when prescribed 499 antidepressants, there was no significant difference in rates of attempted suicide and self-500 harm between SSRIs and TCAs<sup>43,44</sup>. When stratifying by age, we found that the difference 501 in the rate of attempted suicide between SSRIs and TCAs was more pronounced in 502 individuals younger than 25 than in older participants (Supplementary Table 8). Given the 503 retrospective reporting of prescriptions and side effects in our study of a relatively severe 504 study sample, individuals who had suicidal behaviour after taking antidepressants may have 505 failed to respond leading to a potential 'survivorship bias' of our samples. Thus, our results 506 should be interpreted with caution with more evidence needed from other studies. 507

508

509 Our study provides a unique resource to explore the contribution of genetic and medical 510 factors on antidepressant side effects using one of the most powerful and comprehensive 511 self-report records available. Nonetheless, some limitations should be considered. In 512 addition to incomplete metabolic phenotype imputation and limited polygenic prediction due

to available PGSs and sample size mentioned above, the retrospective study design with 513 self-report phenotype is prone to subjective interpretations and recall bias. In the GENDEP 514 clinical trial, antidepressant side effects were shown to be reliably measured with self-report 515 instruments, via good agreement with psychiatrists' ratings. However, this evaluation was 516 limited to the trial period<sup>32</sup>. Linking our data to electronic medical records would allow us to 517 track individuals' antidepressant trajectories through their lifetime with a more precise 518 assessment compared to self-report<sup>45</sup>. Illness perceptions related to antidepressant 519 medication are not available in our data which may be predictive of treatment adherence or 520 continuation<sup>46</sup>. In addition, our data recorded by age did not distinguish whether 521 antidepressants were prescribed simultaneously or not within the same year. Non-522 antidepressant medication data was unavailable limiting the evaluation of polypharmacy 523 524 effects. We also did not collect detailed information on antidepressant dosage, atypical 525 antidepressants (such as Bupropion, Trazodone), or rarer side effects such as myocardial infarction. Finally, our study lacks external validation of models in an independent sample. 526 527 As our results are primarily based on individuals of European ancestry, further analyses are necessary when generalising our findings to other populations with distinct genetic and 528 529 social backgrounds.

530

In conclusion, our study highlighted that self-reported antidepressant side effects and 531 discontinuation can be predicted by incorporating genetic and medical phenotype 532 information, with antidepressant history being a crucial feature. While genetic predictors 533 534 showed a minor impact. larger samples for discovery GWAS of antidepressant phenotypes and advancements in genetics such as long-read sequencing are needed to fully capture 535 their predictive ability. In our analysis, individuals report experiencing different side effect 536 symptoms across antidepressant classes. Further studies with detailed information on 537 antidepressant regimens and combined treatments will enable a full assessment of 538 antidepressant trajectories and the identification of genetic and clinical risk stratification for 539 540 potential individualised clinical applications.

541

#### 542 Data and code availability

543 The GLAD study data are available via a data request application to the NIHR BioResource

- 544 (https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-
- 545 <u>researchers/apply-for-bioresource-data/</u>).

#### 546 547 **Funding**

This work was supported by the National Institute for Health and Care Research (NIHR) 548 BioResource [RG94028, RG85445], NIHR Biomedical Research Centre [IS-BRC-1215-549 20018], HSC R&D Division, Public Health Agency [COM/5516/18], MRC Mental Health Data 550 551 Pathfinder Award (MC\_PC\_17,217), and the National Centre for Mental Health funding through Health and Care Research Wales. Dr Hübel acknowledges funding from 552 Lundbeckfonden (R276-2018-4581). Johan Källberg Zvrskovec acknowledges funding from 553 the National Institute for Health and Care Research (NIHR) Biomedical Research Centre 554 555 and Guy's and St Thomas' NHS Foundation Trust. Prof McIntosh received funding from the Wellcome Trust (226770/Z/22/Z). 556 557

#### 558 Conflict of interest

559 Prof Breen has received honoraria, research or conference grants and consulting fees from 560 Illumina, Otsuka, and COMPASS Pathfinder Ltd. Prof Hotopf is the principal investigator of 561 the RADAR-CNS consortium, an IMI public private partnership, and as such receives 562 research funding from Janssen, UCB, Biogen, Lundbeck and MSD. Prof McIntosh has 563 received research support from Eli Lilly, Janssen, and the Sackler Foundation, and has also 564 received speaker fees from Illumina and Janssen.

565

#### 566 Acknowledgements

567 We thank the GLAD Study and NIHR BioResource volunteers for their participation and gratefully acknowledge the NIHR BioResource centres, NHS Trusts, and staff for their 568 contribution. We thank the National Institute for Health Research, and Health Data Research 569 UK as part of the Digital Innovation Hub Programme. This study presents independent 570 571 research funded by the NIHR Biomedical Research Centre at South London Maudsley NHS Foundation Trust and King's College London. Further information can be found at 572 http://brc.slam.nhs.uk/about/core-facilities/bioresource. The views expressed are those of 573 the authors and not necessarily those of the NHS, the NIHR, the HSC R&D Division, King's 574 College London, or the Department of Health and Social Care. 575 576

#### 577 References

- Kelly, K., Posternak, M. & Jonathan, E. A. Toward achieving optimal response: understanding and managing antidepressant side effects. *Dialogues in Clinical Neuroscience* 10, 409–418 (2008).
- Sansone, R. A. & Sansone, L. A. Antidepressant Adherence: Are Patients Taking Their
   Medications? *Innovations in Clinical Neuroscience* 9, 41–46 (2012).
- Hillhouse, T. M. & Porter, J. H. A brief history of the development of antidepressant drugs:
   From monoamines to glutamate. *Experimental and Clinical Psychopharmacology* 23, 1–21 (2015).
- Wang, S.-M. *et al.* Addressing the Side Effects of Contemporary Antidepressant Drugs: A
   Comprehensive Review. *Chonnam Med J* 54, 101 (2018).
- 5. Hotopf, M., Hardy, R. & Lewis, G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. *Br J Psychiatry* **170**, 120–127 (1997).
- Millan, M. J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
   *Pharmacology & Therapeutics* **110**, 135–370 (2006).
- Kornstein, S. G. *et al.* Gender Differences in Treatment Response to Sertraline Versus
   Imipramine in Chronic Depression. *AJP* 157, 1445–1452 (2000).
- 595 8. De Las Cuevas, C., Peñate, W. & Sanz, E. J. Risk factors for non-adherence to antidepressant 596 treatment in patients with mood disorders. *Eur J Clin Pharmacol* **70**, 89–98 (2014).
- Maggo, S. *et al.* Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety, and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects. *Frontiers in Genetics* 10, 1199 (2019).
- Fabbri, C. *et al.* Effect of cytochrome CYP2C19 metabolizing activity on antidepressant
   response and side effects: Meta-analysis of data from genome-wide association studies.
   *European Neuropsychopharmacology* 28, 945–954 (2018).
- 11. Campos, A. I. *et al.* Understanding genetic risk factors for common side effects of
   antidepressant medications. *Commun Med* 1, 45 (2021).
- Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937 polygenic
   scores. *Nat Commun* 14, 4702 (2023).
- 13. Krapohl, E. *et al.* Multi-polygenic score approach to trait prediction. *Mol Psychiatry* 23, 1368–
  1374 (2018).

- 14. Bzdok, D., Varoquaux, G. & Steyerberg, E. W. Prediction, Not Association, Paves the Road to
   Precision Medicine. *JAMA Psychiatry* **78**, 127 (2021).
- 15. Bzdok, D., Altman, N. & Krzywinski, M. Points of Significance: Statistics versus machine
   learning. *Nature Methods* 15, 233–234 (2018).
- 613 16. Denck, J., Ozkirimli, E. & Wang, K. Machine-learning-based adverse drug event prediction
   614 from observational health data: A review. *Drug Discovery Today* 28, 103715 (2023).
- 515 17. Sajjadian, M. *et al.* Machine learning in the prediction of depression treatment outcomes: a
   516 systematic review and meta-analysis. *Psychol. Med.* 51, 2742–2751 (2021).
- 18. Poweleit, E. A. *et al.* Machine Learning-Based Prediction of Escitalopram and Sertraline Side
  Effects with Pharmacokinetic Data in Children and Adolescents. *Clin Pharma and Therapeutics*cpt.3184 (2024) doi:10.1002/cpt.3184.
- 19. Davies, M. R. *et al.* The Genetic Links to Anxiety and Depression (GLAD) Study: Online
   recruitment into the largest recontactable study of depression and anxiety. *Behaviour Research and Therapy* 123, 103503 (2019).
- 20. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nat Commun* 12, 4192 (2021).
- 625 21. GenoPred at github. https://github.com/opain/GenoPred.
- Bousman, C. A. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline
   for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake
   Inhibitor Antidepressants. *Clin Pharma and Therapeutics* 114, 51–68 (2023).
- 429 23. Hicks, J. K. *et al.* Clinical pharmacogenetics implementation consortium guideline (CPIC) for
   630 CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
   631 *Clinical Pharmacology & Therapeutics* **102**, 37–44 (2017).
- 632 24. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,
  633 scalable and integrative haplotype estimation. *Nat Commun* **10**, 5436 (2019).
- 634 25. Li, D. *et al.* Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant
  635 response from 13 clinical studies using genotype imputation. Preprint at
  636 https://doi.org/10.1101/2023.06.26.23291890 (2023).
- 637 26. Caudle, K. E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus
   638 Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch
   639 Pharmacogenetics Working Group. *Clinical and Translational Science* 13, 116–124 (2020).
- 640 27. Buuren, S. V. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations
   641 in R. *J. Stat. Soft.* 45, (2011).
- 642 28. R Core Team. R: A language and environment for statistical computing. R Foundation for643 Statistical Computing (2023).
- 644 29. Griffin, M. R. Epidemiology of Nonsteroidal Anti-inflammatory Drug–Associated Gastrointestinal
   645 Injury. *The American Journal of Medicine* **104**, 23S-29S (1998).
- 30. Yadesa, T. M., Kitutu, F. E., Tamukong, R. & Alele, P. E. Predictors of hospital-acquired
   adverse drug reactions: a cohort of Ugandan older adults. *BMC Geriatr* 22, 359 (2022).
- Sackeim, H. Vagus Nerve Stimulation (VNS<sup>™</sup>) for Treatment-Resistant Depression Efficacy,
   Side Effects, and Predictors of Outcome. *Neuropsychopharmacology* 25, 713–728 (2001).
- 650 32. Uher, R. et al. Adverse reactions to antidepressants. Br J Psychiatry 195, 202–210 (2009).
- 33. Rheker, J., Winkler, A., Doering, B. K. & Rief, W. Learning to experience side effects after
  antidepressant intake Results from a randomized, controlled, double-blind study. *Psychopharmacology* 234, 329–338 (2017).
- 654 34. Campos, A. I. *et al.* Impact of CYP2C19 metaboliser status on SSRI response: a retrospective
  655 study of 9500 participants of the Australian Genetics of Depression Study. *The*656 *Pharmacogenomics Journal* 22, 130–135 (2022).
- 35. Del Tredici, A. L. *et al.* Frequency of CYP2D6 Alleles Including Structural Variants in the United
   States. *Front. Pharmacol.* 9, 305 (2018).
- 36. Fusar-Poli, L., Rutten, B. P. F., Van Os, J., Aguglia, E. & Guloksuz, S. Polygenic risk scores for
  predicting outcomes and treatment response in psychiatry: hope or hype? *International Review*of *Psychiatry* 34, 663–675 (2022).
- 37. Pain, O. *et al.* Identifying the Common Genetic Basis of Antidepressant Response. *Biological Psychiatry Global Open Science* 2, 115–126 (2022).

- 38. Dudbridge, F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet* 9, e1003348 (2013).
- 39. Pillinger, T. *et al.* Antidepressant and antipsychotic side-effects and personalised prescribing: a
   systematic review and digital tool development. *The Lancet Psychiatry* **10**, 860–876 (2023).
- 40. Reid, S. & Barbui, C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. *BMJ* **340**, c1468–c1468 (2010).
- 41. Edinoff, A. N. *et al.* Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative
   Review. *Neurology International* **13**, 387–401 (2021).
- 42. Fornaro, M. *et al.* The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young
  Adults: More Harm Than Benefits? *Front. Psychiatry* **10**, 294 (2019).
- 674 43. Coupland, C. *et al.* Antidepressant use and risk of adverse outcomes in older people:
  675 population based cohort study. *BMJ* 343, d4551–d4551 (2011).
- 676 44. Coupland, C. *et al.* Antidepressant use and risk of suicide and attempted suicide or self harm in
  677 people aged 20 to 64: cohort study using a primary care database. *BMJ* 350, h517–h517
  678 (2015).
- 45. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics.
   *American J of Med Genetics Pt B* 177, 601–612 (2018).
- 46. Hunot, V. M., Horne, R., Leese, M. N. & Churchill, R. C. A Cohort Study of Adherence to
   Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment
- 683 Preferences. Prim. Care Companion J. Clin. Psychiatry **09**, 91–99 (2007).

# Side effect outcome









**ROC AUC: 0.87** 

0.75

1.00

0.50

1 - specificity

0.25

0.00

1.00

0.75

0.50

0.25

0.00

0.00

Last SSRIs

0.25

0.25

**ROC AUC: 0.73** 

0.75

0.50

1 - specificity

0.00

0.00

1.00



ROC AUC

0.3

0.2

0.1

0.0

Discontinuation Side effects



SSRI SNRI TCA



Symptoms

	Discontinuation	Side effect symptoms	
Prescription at the first year (N (yes%))			
SSRI	3947 (31.6)	4286 (73.3)	
Prescription at the last year (N (yes%))			
SSRI	1770 (20.7)	1986 (75.3)	
SNRI	640 (20.6)	733 (83.5)	
Tricyclic	834 (37.2)	959 (76.4)	

Table 1. Side effects and discontinuation at the prescription of the first and last year